Vatsalya Vatsalya

Prof. Dr. Vatsalya Vatsalya

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2017 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
Irina KirpichIrina Kirpich
Irina Kirpich
CMCraig J. McClain
Craig J. McClain
VVVatsalya Vatsalya
Vatsalya Vatsalya
MSMelanie Schwandt
Melanie Schwandt
MPMonte Phillips
Monte Phillips
JUJohn C. Umhau
John C. Umhau

4 December 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
VVVatsalya Vatsalya
Vatsalya Vatsalya
MCMatthew C. Cave
Matthew C. Cave
MKMaiying Kong
Maiying Kong
LGLeila Gobejishvili
Leila Gobejishvili
KFK. Cameron Falkner
K. Cameron Falkner
CMCraig McClain
Craig McClain

1 September 2018 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
VVVatsalya Vatsalya
Vatsalya Vatsalya
MKMaiying Kong
Maiying Kong
MCMatthew C. Cave
Matthew C. Cave
NLNanlong Liu
Nanlong Liu
MSMelanie L. Schwandt
Melanie L. Schwandt
CMCraig J. McClain
Craig J. McClain

3 April 2023 in American Journal of Gastroenterology
Verified
Journal Article
Open access
THTarek Hassanein
Tarek Hassanein
CMCraig McClain
Craig McClain
VVVatsalya Vatsalya
Vatsalya Vatsalya
LSLance L. Stein
Lance L. Stein
SFSteven L. Flamm
Steven L. Flamm
WLWeiQi Lin
WeiQi Lin
INTRODUCTION: This study is to evaluate the safety and pharmacokinetics (PK) of larsucosterol (DUR-928 or 25HC3S) in subjects with alcohol-associated hepatitis (AH), a devastating acute illness without US Food and Drug Administration–approved therapies. METHODS: This phase 2a, multicenter, open-label, dose escalation study evaluated the safety, PK, and efficacy signals of larsucosterol in 19 clinically diagnosed subjects with AH. Based on the model for end-stage liver disease (MELD) score, 7 subjects were considered to have moderate AH and 12 to have severe AH. All subjects received 1 or 2 intravenous infusions (72 hours apart) of larsucosterol at a dose of 30, 90, or 150 mg and were followed up for 28 days. Efficacy signals from a subgroup of subjects with severe AH were compared with those from 2 matched arms of those with severe AH treated with standard of care (SOC), including corticosteroids, from a contemporaneous study. RESULTS: All 19 larsucosterol-treated subjects survived the 28-day study. Fourteen (74%) of all subjects including 8 (67%) of the subjects with severe AH were discharged ≤72 hours after receiving a single infusion. There were no drug-related serious adverse events nor early terminations due to the treatment. PK profiles were not affected by disease severity. Biochemical parameters improved in most subjects. Serum bilirubin levels declined notably from baseline to day 7 and day 28, and MELD scores were reduced at day 28. The efficacy signals compared favorably with those from 2 matched groups treated with SOC. Lille scores at day 7 were <0.45 in 16 of the 18 (89%) subjects with day 7 samples. Lille scores from 8 subjects with severe AH who received 30 or 90 mg larsucosterol (doses used in phase 2b trial) were statistically significantly lower (P < 0.01) than those from subjects with severe AH treated with SOC from the contemporaneous study. DISCUSSION: Larsucosterol was well tolerated at all 3 doses in subjects with AH without safety concerns. Data from this pilot study showed promising efficacy signals in subjects with AH. Larsucosterol is being evaluated in a phase 2b multicenter, randomized, double-blinded, placebo-controlled (AHFIRM) trial.

2 September 2016 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
VVVatsalya Vatsalya
Vatsalya Vatsalya
MSMing Song
Ming Song
MSMelanie L. Schwandt
Melanie L. Schwandt
MCMatthew C. Cave
Matthew C. Cave
SBShirish S. Barve
Shirish S. Barve
CMCraig J. McClain
Craig J. McClain

9 January 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Joris C VersterJoris C Verster
Joris C Verster
DKDarren Kruisselbrink
Darren Kruisselbrink
KSKarin A. Slot
Karin A. Slot
AAAikaterini Anogeianaki
Aikaterini Anogeianaki
SASally Adams
Sally Adams
ASAnn-Kathrin Stock
Ann-Kathrin Stock
The 2010 Alcohol Hangover Research Group consensus paper defined a cutoff blood alcohol concentration (BAC) of 0.11% as a toxicological threshold indicating that sufficient alcohol had been consumed to develop a hangover. The cutoff was based on previous research and applied mostly in studies comprising student samples. Previously, we showed that sensitivity to hangovers depends on (estimated) BAC during acute intoxication, with a greater percentage of drinkers reporting hangovers at higher BAC levels. However, a substantial number of participants also reported hangovers at comparatively lower BAC levels. This calls the suitability of the 0.11% threshold into question. Recent research has shown that subjective intoxication, i.e., the level of severity of reported drunkenness, and not BAC, is the most important determinant of hangover severity. Non-student samples often have a much lower alcohol intake compared to student samples, and overall BACs often remain below 0.11%. Despite these lower BACs, many non-student participants report having a hangover, especially when their subjective intoxication levels are high. This may be the case when alcohol consumption on the drinking occasion that results in a hangover significantly exceeds their “normal” drinking level, irrespective of whether they meet the 0.11% threshold in any of these conditions. Whereas consumers may have relative tolerance to the adverse effects at their “regular” drinking level, considerably higher alcohol intake—irrespective of the absolute amount—may consequentially result in a next-day hangover. Taken together, these findings suggest that the 0.11% threshold value as a criterion for having a hangover should be abandoned.